Última actualización:
1/24/23
Años publicados: 2019, 2023
NORD gratefully acknowledges Pavlos Msaouel, MD, PhD, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, for the preparation of this report.
Summary
Renal medullary carcinoma, also known as RMC, is a rare cancer of the kidney that predominantly afflicts young people of African descent who carry the sickle cell trait, sickle cell disease or other sickle hemoglobinopathies that can cause sickling of the red blood cells. Renal cell carcinoma, unclassified with medullary phenotype (RCCU-MP) is a very rare subtype of RMC that occurs in people who do not carry any sickle hemoglobinopathies. All RMC and RCCU-MP tumors characteristically do not express a protein called INI1, also known as SMARCB1, hSNF5 or BAF47. Most patients with RMC are young and the cancer will most often have spread to the lymph nodes or other organs by the time it is diagnosed. RMC is twice more likely to occur in men than women, and in the right kidney compared with the left. The most common symptoms are blood in the urine and pain on the kidney side. RMC is treated with chemotherapy, surgery (when feasible) and sometimes radiation therapy. The exact cause of RMC is not fully understood.
Introduction
RMC was originally described in 1995 and is one of the most aggressive kidney cancers. Half of the patients with RMC described in the original 1995 study did not survive longer than 4 months from diagnosis. With current therapies this has improved to 13 months and research is underway to find new and better treatments. RMC can be easier to treat if diagnosed early. Therefore, young black individuals (particularly those who are known to carry the sickle cell trait or sickle cell disease) should immediately contact their healthcare provider if they experience symptoms that can suggest RMC. By the time it is diagnosed, RMC will have spread to the lymph nodes or other organs in more than 90% of patients. If left untreated, RMC can quickly spread to the lymph nodes or other organs even in those patients who initially have RMC contained within the kidney. RMC most commonly spreads to the lymph nodes (85% of patients), lungs (46%), liver (15%) and bone (15%), but almost never spreads to the brain.
The most common first sign of RMC is blood in the urine (hematuria) and patients may also feel pain in their flank around the kidney area or (less commonly) feel a mass in their abdomen, usually on the right side. About half of the patients with RMC will begin losing weight unintentionally and may develop fevers and night sweats.
The exact reason why RMC develops is not fully understood but almost all patients have a blood disorder that can make their red blood cells sickle. These disorders are called “sickle hemoglobinopathies” and include sickle cell trait and sickle cell disease. Of note, most individuals with sickle cell trait are otherwise healthy and many are not aware that they have this blood disorder. Other than the presence of sickle hemoglobinopathy, there are no other known genetic predispositions that can explain why only certain individuals will develop RMC. There is currently no evidence to suggest that family members of a patient with RMC are at increased risk for developing RMC themselves. Although individuals with sickle hemoglobinopathies should take early signs and symptoms of possible RMC very seriously, there are currently no known effective strategies to screen for RMC in individuals without symptoms.
Notably, all RMC tumors lack a protein called INI1, also known as SMARCB1, hSNF5 or BAF47. This protein is also often lost in other rare cancers such as malignant rhabdoid tumors (MRT), atypical teratoid rhabdoid tumors (ATRT) and epithelioid sarcomas. INI1 is a “tumor suppressor” that normally protects cells from turning into cancer.
The red blood cells of individuals with sickle cell disease have changed into a sickle shape throughout the body and this can produce multiple health problems and symptoms unrelated to RMC. On the other hand, the red blood cells of individuals with sickle cell trait change into a sickle shape only in specific locations within the body, such as a part of the kidney called the “renal medulla”. This sickle shape makes red blood cells sticky, rigid and prone to blocking the blood supply of the renal medulla. It is thought that this process can sometimes damage the INI1 gene in cells within the renal medulla thus resulting in RMC. In rare cases, INI1 may be lost in the cells of the renal medulla in individuals without any sickle hemoglobinopathies, thus resulting in a subtype of RMC provisionally called “renal cell carcinoma, unclassified with medullary phenotype” (RCCU-MP).
Recent evidence suggests that high-intensity exercise may be associated with RMC in individuals with sickle cell trait. High-intensity exercise can cause dehydration, low oxygenation and overheating that occasionally lead to serious complications in people with sickle cell trait, including damaging the kidneys in ways that may increase the risk for RMC. High-intensity exercise is defined as increasing your heart rate to 80% or more of your maximum heart rate. The maximum heart rate can be calculated by 220 minus your age. Thus, if you are 30 years old, then your maximum heart rate is 190 beats per minute, and 80% of your maximum heart rate is around 150 beat per minute. High-intensity exercise makes your breathing deep and rapid, you may sweat after just a few minutes of activity, and cannot say more than a few words without pausing for a breath. On the other hand, there is evidence that moderate-intensity exercise may decrease such kidney damage compared with having a sedentary lifestyle. Moderate-intensity exercise is defined as achieving between 50-70% of your maximum heart rate. Such exercise may quicken your breath, but you are not out of breath. Moderate-intensity exercise may make you develop a light sweat after 5-10 minutes of activity, and you can carry on a conversation but cannot sing. Individuals with sickle cell trait can participate in sports with no problems if they drink enough water, take breaks when needed and not overdo it, particularly when starting a new exercise program.
RMC predominantly afflicts young adults and adolescents with sickle cell trait, sickle cell disease or other hemoglobinopathies that can cause red blood cells to change into a sickle shape. In the United States, such sickle hemoglobinopathies are mainly found in individuals of African descent. In other countries such as Greece, sickle hemoglobinopathies are found mainly in Caucasians. The presence of these sickle hemoglobinopathies increases the risk of RMC regardless of race or ethnicity. Men are twice as likely to be affected by RMC than women, and about 70% of RMC cases start from the right kidney. RMC is the third most common kidney cancer among children and young adults. Half of the patients diagnosed with RMC are 28 years old or younger with some being as young as 9 years old. Less commonly, patients can be 35 years old or older.
Although all sickle hemoglobinopathies are risk factors for RMC, the vast majority of patients with RMC have sickle cell trait and only a handful have sickle cell disease or other sickle hemoglobinopathies such as hemoglobin SC disease or sickle beta thalassemia. This may in part be because sickle cell trait is 55 times more common than other sickle hemoglobinopathies. Pure thalassemias, such as alpha or beta thalassemia, are not risk factors for RMC.
About 1 in 14 African Americans carry the sickle cell trait and between 1/20,000 to 1/39,000 of individuals with sickle cell trait will develop RMC. Sickle cell trait is found in approximately 300 million individuals worldwide. The frequency of sickle cell trait varies among different populations and can range from approximately 7% among African Americans, 23.5% in the Chalkidhiki peninsula of Greece, 10% in the Çukurova region of southern Turkey, up to 13% among certain populations in central India, 20% in the eastern province of Saudi Arabia and between 10%-40% across equatorial Africa, reaching up to 45% among the Baamba tribe in Uganda. However, most reports of RMC come from the United States or Europe. This is most likely because RMC is misdiagnosed in other countries, although it is possible that there may be environmental or other local regional risk factors for RMC in the United States and Europe.
Because RMC does not cause symptoms early in the disease, getting an early diagnosis is difficult. Since treatment of RMC can be more effective the earlier the disease is identified, early diagnosis is important.
The diagnosis of RMC should be suspected when a cancer arising from the kidney (most commonly from the right kidney) is found to look under the microscope like a “high-grade, poorly differentiated adenocarcinoma”, particularly if the patient is young and carries the sickle cell trait or other sickle hemoglobinopathies. The cancer tissue should be tested for expression of the INI1 protein using a method called “immunohistochemistry”. If the tissue is negative for INI1 then RMC is confirmed. If the tissue is positive for INI1 then the cancer is not RMC. If the tissue is negative for INI1 but the patient does not carry the sickle cell trait or other sickle hemoglobinopathies then this is the subtype of RMC provisionally called RCCU-MP.
Clinical Testing and Workup
Individuals with sickle cell trait or other sickle hemoglobinopathies who develop signs or symptoms (such as blood in the urine) suggestive of RMC can be evaluated using an ultrasound examination of their kidneys. During an ultrasound, reflected sound waves are used to create an image of the kidneys and other nearby structures. If a mass is found that is suspicious for cancer, then the doctors may recommend advanced imaging techniques such as computed tomography (CT) scan or magnetic resonance imaging (MRI) to further investigate whether this is indeed a cancer. CT and MRI scans use x-rays or magnetic waves, respectively, that are processed by a computer to create images of certain tissue structures, such as the kidneys, within the abdomen and other areas of the body.
If the CT or MRI images show a mass in the kidney that is suspicious for cancer, then doctors may need to take a tiny sample of tissue from the kidney or from other areas that the cancer may have spread to. This is called “biopsy”. During a biopsy, a needle is passed through the skin to take a tiny sample of tumor tissue. The tissue is then studied under the microscope to confirm the diagnosis of RMC. The tissue needs to be tested for the presence or absence of INI1 (also known as SMARCB1, hSNF5 or BAF47) using a method called “immunohistochemistry”.
Treatment
Treatment of RMC may require the coordinated efforts of a team of specialists who will need to plan an affected patient’s treatment systematically and comprehensively. This may include specialists who diagnose and treat cancer (medical oncologists), specialists who perform surgery on the kidney (urologists), specialists who use ionizing radiation to treat cancer (radiation oncologists), specialists who use minimally invasive, image-guide technologies to diagnose and treat cancer (interventional radiologists), as well as other healthcare professionals. Psychosocial support for the entire family is also essential.
Specific therapeutic procedures and interventions may vary, depending upon many factors, such as disease stage (how extensive the disease is), the size of the tumor, the presence or absence of certain symptoms, whether the disease has spread (metastasized) to other areas of the body, an individual’s age and general health and/or other elements. Decisions concerning the use of surgery, radiation, specific drug regimens and/or other treatments should be made by physicians and other members of the health care team in careful consultation with the patient based upon the specifics of their case as well as a thorough discussion of the potential benefits and risks, including possible side effects and long-term effects, patient preferences and other appropriate factors.
RMC is often treated with chemotherapy. Many of the therapies that are used for other kidney cancers do not work against RMC. If CT or MRI imaging suggests that RMC is confined only to the kidney and has not spread to other areas, then surgery can be considered to remove the whole kidney and the cancer inside it. If the RMC tumor is large, for example larger than 4 cm, then doctors may decide to use chemotherapy first in order to shrink the tumor and perform the surgery afterwards, even if there is no evidence on CT or MRI that RMC has spread to other areas. This is because all imaging tests, including CT and MRI, are imperfect and may not detect very small RMC tumors in the lymph nodes or other organs. In these situations, it is hoped that the chemotherapy will treat these areas first, before they are allowed to become too big. Other specific therapeutic procedures may include radiation therapy or other therapies.
Researchers are studying various medications as potential treatments for individuals with RMC. Such treatments include bortezomib and ixazomib, which are drugs that block the removal of unwanted proteins from the cancer cells (proteasome inhibitors), as well as drugs that target certain pathways, such as the EZH2 pathway, that may be important for RMC. In addition, drugs that harness the body’s immune system to recognize and kill RMC cells are also being investigated. Clinical trials are needed to determine the effectiveness and safety of these new therapies for patients with RMC. Clinical trials that enroll patients with RMC will normally also enroll patients with the RCCU-MP subtype.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact:
www.centerwatch.com
For more information about clinical trials conducted in Europe contact:
https://www.clinicaltrialsregister.eu/
TEXTBOOKS
Msaouel P, Rao P, Tannir NM. Renal Medullary Carcinoma. In: Malouf GG, Tannir NM, editors. Rare Kidney Tumors: Comprehensive Multidisciplinary Management and Emerging Therapies. Cham: Springer International Publishing; 2019. p. 65-75. https://link.springer.com/chapter/10.1007/978-3-319-96989-3_6
JOURNAL ARTICLES
Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, et al. Association of high-intensity exercise with renal medullary carcinoma in individuals with sickle cell trait: clinical observations and experimental animal studies. Cancers (Basel). 2021;13(23):6022. https://pubmed.ncbi.nlm.nih.gov/34885132/
Tan KT, Kim H, Carrot-Zhang J, Zhang Y, Kim WJ, Kugener G, Wala JA, et al. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021; 13(1):114. https://pubmed.ncbi.nlm.nih.gov/34261517/
Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao, et al. Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma. Cancer Cell. 2020;37(5):720-734. https://pubmed.ncbi.nlm.nih.gov/32359397/
Msaouel P, Carugo A, Genovese G. Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next? Oncotarget. 2019;10(40):3979-81. https://www.ncbi.nlm.nih.gov/pubmed/31258836
Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, et al. Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma. Clin Genitourin Cancer. 2019;17(1):1-6. https://www.ncbi.nlm.nih.gov/pubmed/30287223
Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, et al. The classification of pediatric and young adult renal cell carcinomas registered on the children’s oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018;124(16):3381-9. https://www.ncbi.nlm.nih.gov/pubmed/29905933
Msaouel P, Tannir NM, Walker CL. A model linking sickle cell hemoglobinopathies and SMARCB1 loss in renal medullary carcinoma. Clin Cancer Res. 2018;24(9):2044-9. https://www.ncbi.nlm.nih.gov/pubmed/29440190
Ohe C, Smith SC, Sirohi D, Divatia M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, andfFumarate hydratase-deficient renal cell carcinoma. Am J Surg Pathol. 2018;42(3):279-92. https://www.ncbi.nlm.nih.gov/pubmed/29309300
Beckermann KE, Sharma D, Chaturvedi S, et al. Renal medullary carcinoma: establishing standards in practice. J Oncol Pract 2017;13:414-21. https://www.ncbi.nlm.nih.gov/pubmed/28697319
Shah AY, Karam JA, Malouf GG, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU international 2017;120:782-92. https://www.ncbi.nlm.nih.gov/pubmed/27860149
Calderaro J, Masliah-Planchon J, Richer W, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas. European urology 2016;69:1055-61. https://www.ncbi.nlm.nih.gov/pubmed/26433572
Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer 2015;62:1694-9. https://www.ncbi.nlm.nih.gov/pubmed/26053587
Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Canadian Urological Association Journal 2015;9:E172-7. https://www.ncbi.nlm.nih.gov/pubmed/26085875
Amin MB, Smith SC, Agaimy A, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. American Journal of Surgical Pathology 2014;38:871-4. https://www.ncbi.nlm.nih.gov/pubmed/24805860
Smith NE, Deyrup AT, Marino-Enriquez A, et al. VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? American Journal of Surgical Pathology 2014;38:858-63. https://www.ncbi.nlm.nih.gov/pubmed/24698962
Davis CJ, Jr., Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. American Journal of Surgical Pathology 1995;19:1-11. https://www.ncbi.nlm.nih.gov/pubmed/7528470
NORD y la Fundación MedicAlert se han asociado en un nuevo programa para brindar protección a pacientes con enfermedades raras en situaciones de emergencia.
Aprende más https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Asegurarse de que los pacientes y los cuidadores estén equipados con las herramientas que necesitan para vivir su mejor vida mientras manejan su condición rara es una parte vital de la misión de NORD.
Aprende más https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/Este programa de asistencia, primero en su tipo, está diseñado para los cuidadores de un niño o adulto diagnosticado con un trastorno raro.
Aprende más https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View report